Comparing transplant outcomes with different immune suppression approaches
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well different ways of preparing for a stem cell transplant work, focusing on using a special treatment to remove certain cells from the donor stem cells. It aims to see if a newer, personalized dosing of a medicine that prevents graft-versus-host disease is better than the standard approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant between 2021 and 2023 in the US.
- You were between 1 and 65 years old at the time of transplant.
- You had a blood cancer like AML, MDS, or ALL and were in complete remission.
- Your donor was a fully matched related or unrelated donor.
- You received a stem cell transplant from peripheral blood (not bone marrow).
- You received a myeloablative (high-intensity) conditioning regimen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial compares two chemotherapy drugs, treosulfan and melphalan, used before a stem cell transplant in people with AML or MDS. The goal is to see which one works better with a special anti-rejection drug called PTCy.
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.